A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006)

Trial details

Who runs it

Merck Sharp & Dohme LLC

Trial code

EU 2023-505520-61-00

Record updated

2025. július 23.

Original description

1. To evaluate the efficacy of MK-6194 compared to placebo as assessed by the proportion of participants with SRI-4 response at Week 28. 2. To evaluate the safety and tolerability of MK-6194.Read full original descriptionShow less

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus

1. To evaluate the efficacy of MK-6194 compared to placebo as assessed by the proportion of participants with SRI-4 response at Week 28. 2. To evaluate the safety and tolerability of MK-6194.

Inclusion: Has a diagnosis of systemic lupus erythematosus (SLE) ≥6 months prior to Screening; Is taking at least 1 background therapy (1 immunosuppressant or dapsone and/or 1 antimalarial and/or oral corticosteroids) for SLE; Has + antinuclear antibody (+ANA) (titer ≥1:80) or positive anti-double-strand deoxyribonucleic acid (dsDNA) antibody or positive anti-Sm antibody, or positive anti-SSA/Ro antibody; Has the presence of at least one of the following manifestations of SLE: Active lupus rash with CLASI-A erythema and scale/hypertrophy combined score >2, or >2 tender and swollen joints in wrists, metacarpophalangeals (MCPs), or proximal interphalangeals (PIPs); Has a hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score of ≥6 and clinical hybrid SLEDAI score of ≥4.

Exclusion: Has an active or clinically significant infection, requiring hospitalization or treatment with anti-infectives; Has had major surgery within 3 months prior to Screening or has a major surgery planned during the study; Is taking more than 1 oral NSAID (excluding low-dose aspirin [<350 mg/day]) or is taking daily oral nonsteroidal anti-inflammatory drug (NSAID) at greater than the maximum recommended dosage; Is currently on any chronic systemic (oral or IV) anti-infective therapy for chronic active infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria); Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening; Has drug-induced cutaneous lupus erythematosus (CLE) and/or drug-induced SLE in the setting of continued treatment with a causative agent; Has a diagnosis of Antiphospholipid Syndrome with history of vascular thrombosis, catastrophic APS, or pregnancy morbidity within 6 months prior to Screening; Has a history of any malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix; Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB; Has confirmed or suspected COVID-19 infection; Has a severe chronic pulmonary disease requiring oxygen therapy; Has a known systemic hypersensitivity to IL-2, or modified IL-2 including MK-6194, or its inactive ingredients; Has a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly; Has active or unstable neuropsychiatric lupus including but not limited to the following: seizure, new or worsening impaired level of consciousness, psychosis, delirium or confused state, aseptic meningitis, cranial neuropathy, cerebrovascular accident, ascending or transverse myelitis, chorea, cerebellar ataxia, mononeuritis multiplex, or demyelinating syndromes; Has a concurrent clinically significant disease or clinically relevant laboratory abnormalities, or a history of any illness or medical condition that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study; Is taking more than 1 immunosuppressant; Has a transplanted organ which requires continued immunosuppression.

EU CTIS 2023-505520-61-00